In Vitro Synergistic Activities of the Hybrid Anti

Authors: Ammar Almaaytah Adan Alnaamneh Ahmad Abualhaijaa Nizar Alshari’ Qosay AlBalas

Publish Date: 2016/05/11

Volume: 22, Issue: 4, Pages: 497-504

PDF Link

Abstract

The extensive use of antibiotics for the treatment of human infections during the last few decades has led to a dramatic increase in the emergence of multidrugresistant bacteria MDRB among various bacterial strains Global research is currently focused on finding novel alternative agents with different mechanisms of action rather than the use of conventional antibiotics to counteract the threat of bacterial and biofilm infections Antimicrobial peptides represent promising alternative agents for conventional antibiotics as these molecules display a broad spectrum of activity against several microorganisms Recently we have designed a novel hybrid antimicrobial peptide named MelitAP27 This peptide has been found to display potent broad spectrum and selective in vitro antimicrobial activities against a wide range of Grampositive and Gramnegative bacteria In the present study the in vitro antimicrobial and antibiofilm activities of the peptide alone and in combination with five different types of antibiotics were assessed against wildtype and resistant Grampositive and Gramnegative bacterial strains Our results showed that most of the combination groups displayed a synergistic mode of action against planktonic and biofilm forming bacteria which resulted in decreasing the effective MIC values for MelitAP27 to the nanomolar concentrations These effective concentrations were associated with negligible toxicities on mammalian cells The results of our study indicate that combinations of MelitAP27 with conventional antibiotics may be pursued as a potential novel treatment strategy against MDRB and biofilm forming bacteriaAll of the authors involved in this manuscript declare that they have no conflict of interest The authors that they have no affiliations with or involvement in any organization or entity with any financial interest such as honoraria educational grants participation in speakers’ bureaus membership employment consultancies stock ownership or other equity interest and expert testimony or patentlicensing arrangements in the subject matter or materials discussed in this manuscript

Keywords: